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Abstract
Bisphosphonates (BPs) anti-fracture efficacy 
may be due in part to inhibition of osteocyte 
apoptosis. This effect requires opening of con-
nexin (Cx) 43 hemichannels and phosphoryla-
tion of the extracellular signal regulated kinases 
(ERKs). However, unlike ERK activation by other 
stimuli, the Cx43/ERK pathway activated by BPs 
does not result in nuclear ERK accumulation. In-
stead, the anti-apoptotic effect of BPs depends 
on phosphorylation of cytoplasmic ERK targets 
and is abolished by forced nuclear retention of 
ERKs. We now report that ERKs and the scaf-
folding protein β-arrestin co-immuno-precipitate 
with Cx43 in MLO-Y4 osteocytic cells and that 
the BP alendronate increases this association. 
Moreover, ERK2 fused to red fluorescent pro-
tein (ERK2-RFP) co-localizes with Cx43 fused 
to green fluorescent protein outside the nucleus 
in cells untreated or treated with alendronate. 
Alendronate does not induce ERK nuclear ac-
cumulation in cells transfected with wild type 
β-arrestin (wtARR) or vector control, whereas 
it does in cells expressing a dominant nega-
tive β-arrestin mutant (dnARR) consisting of the 
β-arrestin-clathrin binding domain that com-
petes with endogenous β-arrestin for binding to 
* Correo electrónico: lplotkin@iupui.edu # Current address: IMMA Facultad de Medicina, Universidad San 
Pablo CEU, 28868 Boadilla del Monte, Madrid, Spain
clathrin. Alendronate activates ERKs in dnARR-
transfected cells as effectively as in cells trans-
fected with wtARR, demonstrating that dnARR 
only interferes with subcellular localization but 
not with activation of ERKs by BPs. Further, 
whereas alendronate inhibits apoptosis in cells 
expressing wtARR or vector control, it is inef-
fective in cells expressing dnARR. Thus, BPs 
induce the formation of a complex comprising 
Cx43, β-arrestin, and clathrin, which directs 
ERKs outside the nucleus and is indispensable 
for osteocyte survival induced by BPs. 
Key words: osteocyte, bisphosphonate, be-
ta-arrestin, apoptosis
Resumen
EL COMPLEJO β-ARRESTINA/CONEXINA 43 
(Cx43) RETIENE ERKS FUERA DEL NÚCLEO: 
UN PASO NECESARIO PARA EL EFECTO AN-
TI-APOPTÓTICO DE LOS BISFOSFONATOS 
MEDIADO POR Cx34/ERK EN OSTEOCITOS
La efectividad de los bisfosfonatos (BPs) en 
la prevención de fracturas puede deberse en 
parte a la inhibición de la apoptosis de osteoci-
tos. Este efecto depende de la apertura de he-
micanales de conexina (Cx) 43 y la fosforilación 
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de quinasas reguladas por señales extracelula-
res (ERKs). Sin embargo, a diferencia de la acti-
vación de ERKs debida a otros estímulos, la vía 
de señalización Cx43/ERK activada por BPs no 
conlleva la acumulación de ERKs en el núcleo. 
El efecto anti-apoptótico de los BPs depende 
de la fosforilación de blancos citoplasmáticos 
de ERKs y es inhibido cuando las quinasas son 
retenidas en el núcleo. En este estudio hemos 
demostrado que ERKs y la proteína “scaffol-
ding” β-arrestina co-inmunoprecipitan con 
Cx43 en células osteocíticas MLO-Y4 y que 
alendronato aumenta esta asociación. Más 
aún, ERK2 fusionada a la proteína roja fluores-
cente (ERK2-RFP) co-localiza con Cx43 fusio-
nada con la proteína verde fluorescente fuera 
del núcleo en células tratadas con vehículo o 
alendronato. Alendronato no indujo la acumu-
lación nuclear de ERK en células transfectadas 
con β-arrestina nativa (wtARR) o con un vector 
control, pero si lo hizo en células que expresan 
una forma dominante negativa de β-arrestina 
(dnARR), consistente en el dominio de interac-
ción entre β-arrestina y clatrina, y que compite 
con β-arrestina endógena por la unión a clatri-
na. Alendronato activa ERKs con la misma efi-
ciencia en células transfectadas con dnARR o 
wtARR, demostrando que dnARR sólo interfie-
re con la localización subcelular de ERKs, pero 
no con su activación inducida por los BPs. Más 
aún, mientras alendronato inhibe apoptosis en 
células que expresan wtARR o vector control, 
es inefectivo en células que expresan dnARR. 
En conclusión, los BPs inducen la formación 
de un complejo que incluye Cx43, β-arrestina 
y clatrina, el cual retiene ERKs fuera del núcleo 
y es indispensable para la sobrevida de los os-
teocitos inducida por estas drogas.
Palabras clave: osteocito, bifosfonatos, be-
ta-arrestina, apoptosis
Introduction
Bisphosphonates (BPs) are drugs used 
to preserve bone mass due to their inhibitory 
effects on osteoclast function, and therefore, 
act as anti-resorptive agents.1 Reduced 
osteoclast viability induced by BPs occurs 
as a consequence of the inhibition of the 
mevalonate pathway, or to formation of 
toxic intracellular metabolites. However, the 
efficacy of BPs on the prevention of bone 
fractures cannot be explained completely by 
their effect on bone resorption. We and others 
have shown that bisphosphonates prevent 
osteoblast and osteocyte apoptosis induced 
by the glucocorticoid dexamethasone, the 
topoisomerase inhibitor etoposide, and the 
cytokine tumor necrosis alpha in vitro, and 
induced by glucocorticoid excess and by 
lack or excessive mechanical forces in vivo,2,3 
raising the possibility that preservation of the 
osteocyte network might contribute to the 
beneficial effects of BPs on the skeleton.4 
The mechanism for the survival effect of 
these agents on osteoblastic cells differs from 
the one by which BPs inhibit the function of 
osteoclasts. Thus, the concentration required 
for the effect of BPs on osteoblastic cells is 
several orders of magnitude lower than the 
one required to induce osteoclast apoptosis. 
Further, the anti-apoptotic effect of BPs on 
osteoblastic cells can be dissociated from 
the effect of the drugs on osteoclast using 
BP analogs. In particular, IG9402, a BP that 
does not inhibit the mevalonate pathway or 
affect osteoclast viability in vitro,5,6 does not 
affect bone remodeling but was as effective as 
alendronate in activating ERKs and preventing 
osteoblast and osteocyte apoptosis and the 
decrease in bone mass and strength induced 
by glucocorticoids.6 Furthermore, IG9402 
is able to prevent osteocyte apoptosis and 
partially preserve bone strength, without 
affecting bone resorption in mice unloaded by 
tail suspension.3 
The role of connexin channels in bone 
cells, and in particular in osteoblasts and 
osteocytes, have been extensively study, 
both in vitro and in vivo.7-12 Cx43 is required 
for osteoblast and osteoclast differentiation, 
and for the viability of osteocytes.13-15 Further, 
Cx43 can regulate the expression of genes 
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required for osteoblast differentiation directly 
in osteoblast altering the levels of Runx2 and 
osteocalcin,13,14,16 or through the regulation of 
genes that control osteoblast differentiation 
in osteocytes, such as Sost/sclerostin.17,18 In 
addition, Cx43 regulates the expression of 
cytokines required for osteoclast differentia-
tion in osteoblastic cells, and Cx43 deletion 
results in increased expression of the pro-os-
teoclastogenic cytokine receptor activator of 
nuclear factor kappa-B ligand (RANKL) and 
in decreased expression of the anti-osteo-
clastogenic cytokine osteoprotegerin (OPG), 
resulting in a cytokine ratio that favors osteo-
clast differentiation.17-19 Furthermore, Cx43 
channels are required for osteoclast differen-
tiation.20,21 and deletion of Cx43 from osteo-
clast progenitors inhibit their differentiation in 
vivo.22 
Previous evidence demonstrated that 
inhibition of osteocyte apoptosis by BPs 
is mediated via a novel paradigm of signal 
transduction involving connexin (Cx) 43 
hemichannels and the subsequent activation 
of ERKs.23 In addition, we found that unlike 
other ERK activators such as estradiol, 
BPs do not cause nuclear accumulation 
of ERKs.24 And, moreover, forced nuclear 
retention of the kinases abolishes the survival 
effect of BPs. However, the mechanism of 
the extra-nuclear retention of ERKs remained 
heretofore unknown. 
β-arrestins are scaffolding proteins that 
bind to seven-transmembrane G protein-
coupled receptors and to clathrin.25 This 
interaction results in receptor internalization 
leading to recycling of the receptor to the 
cell surface or to its degradation, and the 
desensitization of the cell to the action of the 
receptor ligand. This mechanism modulates 
the actions of hormones, cytokines, and 
pharmacological agents, including parathyroid 
hormone, calcitonin, hepatocyte growth 
factor, and agonists of the β2-adrenergic 
receptors. More recent evidence indicate that 
β-arrestins also act as scaffolds for intracellular 
signaling kinases, interacting with Src and 
ERKs, resulting in extra-nuclear retention the 
kinases. Furthermore, we have shown that the 
interaction of Cx43 with β-arrestin is required 
for cAMP-mediated gene transcription and the 
anti-apoptotic effect of parathyroid hormone 
in osteoblastic cells.26
Based on the absolute requirement of 
Cx43 for the anti-apoptotic effect of BPs,23,27 
we hypothesized that ERKs activated by BPs 
are retained outside the nucleus by forming a 
complex with Cx43 and associated scaffolding 
proteins. In this study we examined whether 
β-arrestins associate with Cx43 and whether 
this complex is involved in the anti-apoptotic 
effect of BPs mediated by ERKs.
Materials and Methods
Cell culture
MLO-Y4 osteocytic cells derived from mu-
rine long bones were cultured as previously 
described.4;28 Cells were maintained in α-MEM 
medium containing L-glutamine and 1 % v/v 
penicillin/streptomycin (Gibco), 10 % heat in-
activated fetal bovine serum (Hyclone). 
DNA constructs and transient transfection
The constructs encoding the nuclear green 
fluorescent protein (nGFP) or the nuclear red 
fluorescent protein (nRFP) were previously 
described.4,29 Cx43-GFP was provided by D. 
Laird (University of Western Ontario, London, 
Ontario, Canada).30 Wild-type mitogen-
activated protein kinase/extracellular signal-
regulated kinase kinase (MEK) was provided 
by N. G. Ahn (University of Colorado, Boulder, 
CO).31 ERK-RFP was provided by L. Luttrell 
(Medical University of South Carolina, 
Charleston, SC).32 Wild type β-arrestin 
and β-arrestin319-418 (dnARR) constructs 
were provided by K. DeFea (University of 
California, Riverside, CA).33 These constructs 
have been shown to be normally expressed 
at the protein and mRNA levels. Cells were 
transiently transfected using Lipofectamine 
Plus (Invitrogen) as previously described.23 
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The efficiency of transfection was ∼70%, as 
determined by quantifying cells expressing 
or not the fluorescent proteins under a 
fluorescence microscope. 
Quantification of apoptotic cells
Apoptosis was induced in semi-confluent 
cultures (less than 75% confluence). Cells 
were treated with vehicle or 10-7 M alendronate 
for 1 h, followed by treatment with 50 μM 
etoposide for 6 h, as previously reported.23 
The concentration of alendronate and 
etoposide were chosen based on previous 
studies showing a maximum effect for both 
agents in MLO-Y4 osteocytic cells. Apoptosis 
was assessed by enumerating MLO-Y4 
cells expressing nRFP exhibiting chromatin 
condensation and nuclear fragmentation under 
a fluorescence microscope. At least 250 cells 
from fields selected by systematic random 
sampling for each experimental condition 
were examined. The percentage of apoptosis 
was calculated using the formula (% DCe+s - % 
DCs) / (% DCe - % DCv) x 100, where DC = 
dead cells, e = etoposide-treated cultures, s = 
alendronate- or 17βestradiol-treated cultures 
and v = vehicle-treated cultures, as previously 
published.23,29
Sub-cellular localization of ERK
MLO-Y4 cells were transiently transfected 
with ERK2-RFP to allow the visualization 
of ERK and wild type MEK to anchor 
inactive ERK2 in the cytoplasm. Following 
transfection, cells were cultured in growth 
medium for 40 h, followed by incubation with 
α-MEM containing 10-7 M alendronate or 10-7 
M 17β-estradiol for 30 min. The percentage 
of cells showing nuclear accumulation of 
ERK2-RFP was quantified by enumerating 
cells exhibiting increased RFP in the 
nucleus compared to the cytoplasm, using 
a fluorescence microscope. At least 250 
cells from fields selected by systematic 
random sampling were examined for each 
experimental condition.
Western Blot analysis and immunoprecipi-
tation
Western blots were performed using a 
rabbit anti-Cx43 antibody (Sigma, St. Louis, 
MO), rabbit anti-ERK, goat anti-β-arrestin1, 
and mouse anti-GFP antibodies (Santa Cruz 
Biotechnology, Santa Cruz, CA), following 
published protocols.23;26 The intensity of the 
bands was quantified using the Fotodyne 
system (Hartland, WI). Each plate was lysed 
with 0.1 ml of RIPA buffer (150 mM NaCl, 1.0% 
IGEPAL® CA-630, 0.5% sodium deoxycholate, 
0.1% SDS, 50 mM Tris, pH 8.0, Sigma 
Chemical Co., St. Louis, MO) supplemented 
with phosphatase inhibitors (sodium fluoride, 
sodium orthovanadate) and protease inhibitors 
(leupeptin, aprotinin). Immunoprecipitation 
was performed using 600 μg of extracts and 
2 µg of anti-Cx43 (Sigma), overnight at 4°C. 
Complexes were collected with 50 µl of 25% 
slurry of protein-G agarose beads (Santa Cruz 
Biotechnology).
Statistical analysis
Data were analyzed by one-way ANOVA, 
and the Student-Newman-Keuls method was 
used to estimate the level of significance of 
differences between means.
Results
First, we examined whether ERKs and Cx43 
exhibit the same sub-cellular localization. For 
this, MLO-Y4 osteocytic cells were transfected 
with Cx43 fused to GFP together with ERK2 
fused to RFP (Figure 1A). The localization of the 
molecules was visualized under a fluorescence 
microscope. Cx43 was found in discrete areas 
outside the nucleus in un-stimulated cells. This 
distribution did not change upon treatment 
with alendronate or 17-βestradiol. ERK2-RFP 
localized outside the nucleus in vehicle as 
well as alendronate-treated cells. Therefore, 
the merge images show that ERK2-RFP co-
localizes with Cx43-GFP outside the nucleus 
in both untreated and alendronate-treated 
cells. On the other hand, ERK2-RFP localized 
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in the nucleus in 17-βestradiol-treated cells. 
These results raised the possibility that ERKs 
interact with Cx43 in the presence of BPs. 
Western blot analysis showed that alendronate 
treatment for 2 or 5 min did not affect the total 
amount of ERK, β-arrestin-1 or Cx43 present 
in MLO-Y4 cell lysates (Figure 1B). In addition, 
we found that ERKs and β-arrestin-1 co-
immunoprecipitated with Cx43 in the absence 
of BP and the association among these proteins 
was increased in the presence of alendronate.
We then determine the participation of 
β-arrestin in the anti-apoptotic effect of BPs. 
For this experiments, we used etoposide 
as pro-apoptotic agents since we have 
extensively used it and consistently increase 
apoptosis of MLO-Y4 osteocytic cells.4,5,23,24 
We transiently transfected MLO-Y4 osteocytic 
cells with 2 different constructs, wild type or 
dominant negative β-arrestin, both tagged 
with GFP (Figure 2). In addition, cells were 
transfected with GFP as vector control. The 
wild type β-arrestin construct renders a protein 
of 75 kD, which localizes in the cytoplasm, 
with no detectable localization at the plasma 
membrane (Figure 2A). GFP-tagged dnARR 
consists of aminoacids 319-418 and renders a 
protein of 40 kD, with a punctuate distribution 
throughout the cell which resembles the 
distribution of clathrin. This mutant comprises 
only the clathrin binding domain of β-arrestin 
and act as a dominant negative by competing 
with endogenous β-arrestin for binding to 
clathrin. Both wild type and dominant negative 
β-arrestin were expressed at similar levels, as 
determined by Western blotting using anti-
green fluorescent protein antibodies.
Overexpression of β-arrestin-1 constructs 
did not interfere with alendronate-induced 
ERK activation. Thus, 2-min treatment with 
alendronate induced similar increases in ERK 
phosphorylation in un-transfected cells than in 
cells expressing wild type or dominant negative 
β-arrestin (Figure 2B). As shown before,24 
Figure 1. Cx43 interacts with β-arrestin and ERKs in the cytoplasm of MLO-Y4 osteocytic cells, 
an interaction that is rapidly enhanced by alendronate treatment. (A) MLO-Y4 cells were transiently 
transfected with the indicated constructs and treated with 10-7 M alendronate or 17β-estradiol for 2 
minutes. Cells were fixed and observed under a fluorescence microscope. (B) Cells were treated with 
alendronate for the indicated times, and Cx43 was immuno-precipitated as indicated in the methods 
section. Western blot analysis was performed with the whole lysates (input) or with protein extracts after 
immunoprecipitation with non-immune (ni) IgG as control or with anti-Cx43 antibodies. Western blot (WB) 
analysis was performed using the indicated antibodies. 
A B
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alendronate did not induce ERK nuclear 
accumulation in cells transfected with GFP, 
whereas 17β-estradiol increase the percentage 
of cells exhibiting nuclear accumulation of the 
kinase (Figure 2C). Similarly, alendronate did 
not induce nuclear accumulation of ERKs 
in cells expressing wild type β-arrestin, 
whereas it did increase nuclear accumulation 
Figure 2. Blockade of endogenous β-arrestin interaction with clathrin using a dominant negative 
β-arrestin abolishes ERK extra-nuclear retention and anti-apoptosis induced by BPs. (A) MLO-Y4 
osteocytic cells were transiently transfected with GFP (vector control), or GFP-tagged wild type β-arrestin 
(wt) or the dominant negative truncated molecule (dn) together with RFP targeted to the nucleus (nRFP). 
Forty-eight hours after transfection cells were either treated to obtain proteins lysates or fixed. Protein 
lysates were analyzed by Western blotting using an anti-GFP antibody. Fixed cells were observed under 
fluorescence microscope. (B) MLO-Y4 osteocytic cells were left un-transfected or transfected with wt 
or dn β-arrestin-1-GFP. Forty eight hours after transfection, cells were treated with vehicle or 10-7 M 
alendronate for 2 minutes and protein lysates were prepared. The levels of phosphorylate ERKs (pERKs) 
were analyzed by Western blotting using specific antibodies and corrected by the level of total ERKs. (C) 
MLO-Y4 osteocytic cells were transiently transfected with the indicated constructs together with nRFP. 
Forty eight hours later, cells were treated with vehicle, 10-7 M alendronate or 17β-estradiol for 2 minutes, or 
treated with the reagents for 30 min, followed by a 6-h treatment with the pro-apoptotic agent etoposide 
(50 μM). Subsequently, cells were fixed and scored under a fluorescence microscope. 
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of ERKs in cells expressing the dominant 
negative construct. In contrast, neither 
wild type nor dominant negative β-arrestin 
altered 17β-estradiol-induced nuclear ERK 
accumulation. Consistent with the requirement 
of extra-nuclear localization of ERKs for the 
survival effect of BPs, alendronate did not 
inhibit apoptosis induced by etoposide in cells 
expressing the dnARR mutant, whereas it 
prevented apoptosis in cells expressing GFP or 
wild type β-arrestin. The anti-apoptotic effect 
of 17β-estradiol was not affected by either 
dominant negative or wild type β-arrestin. 
Taken together, these results indicate the 
specificity of the cross-talk between β-arrestin 
and the Cx43/ERK pathway. 
Discussion
The studies reported herein demonstrate 
that Cx43 co-localizes with ERKs outside the 
nucleus in untreated cells or in cells treated 
with alendronate; and that alendronate induces 
the association of Cx43 with β-arrestin-1 and 
ERKs (Figure 3). Furthermore, inhibition of the 
association of β-arrestin with clathrin prevents 
alendronate-induced extra-nuclear localization 
of ERKs and anti-apoptosis. On the other hand, 
wild type or dominant negative β-arrestin-1 did 
not affect ERK sub-cellular localization or anti-
apoptosis induced by 17β-estradiol, adding 
further evidence for the distinct mechanism of 
action of the two types of anti-resorptive drugs 
in osteocytic cells.
Figure 3. Working model. β-arrestin forms a complex with Cx43 and clathrin that also encompass Src, 
which retains ERKs activated by BPs outside the nucleus. This complex favors the activation of the 
cytoplasmic target of ERKs p90RSK, and the phosphorylation of C/EBPβ and BAD, resulting in osteocyte 
(and osteoblast) survival. 
BPs are widely used for the treatment of 
conditions associated with low bone mass.1 
Their beneficial effects are a consequence 
of the reduction in bone resorption due to 
inhibition of osteoclast function. In addition, 
BPs prevent osteocyte and osteoblast 
apoptosis, an effect that can contribute to the 
anti-fracture efficacy of these drugs.2 Indeed, 
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administration of a BP analog that does 
affect osteoclasts but prevents osteocyte and 
osteoblast apoptosis is able to prevent the 
decrease in bone mass and strength induced 
by glucocorticoid excess in mice.5,6,34 As the 
classical BPs, this novel analog requires the 
expression of Cx43 to prevent osteocyte and 
osteoblast apoptosis.5 Even though receptors 
for BPs have not been described, these 
agents bind to the cell surface in a specific 
and saturable manner.35 However, the binding 
is independent of the expression of Cx43, 
indicating that another molecule binds to BPs, 
leading to opening of Cx43 hemichannels, 
and the activation the Src/MEK/ERK signaling 
pathway, followed by the phosphorylation 
of cytoplasmic targets of the kinases and 
cell survival. This survival signaling pathway 
mediated by kinases does not required new 
gene transcription.24 This contrasts with the 
anti-apoptotic effect of sex steroids, which 
also requires Src/MEK/ERK activation, but 
is abolished when ERKs are retained in the 
cytoplasm or when new gene transcription is 
inhibited.24,36 We now show that retention of 
ERKs in the cytoplasm and osteocyte survival 
induced by BPs requires the association 
among Cx43, β-arrestin and clathrin.
We have previously reported that the 
association between Cx43 and β-arrestin 
is required for the survival effect of PTH 
in osteoblastic cells.26 However, the anti-
apoptotic effect of PTH does not require ERK 
activation and, instead, it is mediated by new 
gene transcription downstream of cAMP 
activation.37 In this context, Cx43 sequesters 
β-arrestin, preventing its binding to the PTH 
receptor and, therefore, the inhibition of PTH-
induced, cAMP-mediate gene transcription.26 
Thus, β-arrestin contributes to osteocyte and 
osteoblast survival by at least two different 
means: by allowing the activation of the 
cAMP/PKA pathway in the presence of PTH, 
and by retaining ERK activated by BPs in the 
cytoplasm, without affecting the activation 
of the kinase. These actions of β-arrestins 
in osteoblastic cells add to the discoveries 
on the novel actions of β-arrestins, not only 
as molecules involved in desensitization 
of G protein-coupled receptors and their 
internalization, but also as scaffolds for 
intracellular kinases and targets of novel 
agonists.25 These agonists that can activate 
arrestin-selective signaling downstream of 
the seven-transmembrane receptors, without 
activating G-protein-mediated signaling are 
named “biased agonists”. Taken together, 
these pieces of evidence suggest that BPs 
can be considered a new class of biased 
β-arrestin agonist, although the identity of the 
receptor activated by these agents remains to 
be determined. 
In conclusion, our study adds to the 
functions of Cx43 as a scaffolding molecule 
that binds intracellular structural and signaling 
molecules. Based on the evidence presented 
here and our previous studies,23,24 we proposed 
that, through its C-terminus domain, Cx43 
binds to β-arrestin and forms a complex with 
clathrin, Src and MEK, leading to activation 
of ERKs and their retention in the cytoplasm 
(Figure 3). This signaling cascade leads to the 
activation of p90RSK and the phosphorylation 
of C/EBPβ and Bad. Phosphorylated C/EBPβ 
binds and blocks active caspase3, whereas 
phosphorylated Bad is inactive, resulting 
in anti-apoptotic signaling and osteoblast/
osteocyte survival.
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